Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.

"Declarations Conflict of interestThe authors have no relevant financial or non-financial interests to disclose. Consent to participateInformed consent was obtained from all individual participants included in the study. Ethical approvalThe present study involving human tissues was approved by the Ethics Committee of the First People's Hospital of Foshan, Guangdong. The studies were conducted in accordance with local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Conflict of interest The authors have no relevant financial or non-financial interests to disclose."

"Funding The present study was funded by the Clinical Characteristic Technology Project of Guangzhou (grant no. 2023C-TS45), the Special Fund of the Foshan Summit Plan (grant no. 2019C020)."